Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (À5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q-syndrome among MDS patients was 8.4 and 1.3%, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in À5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS.
Introduction
Loss of part of the long arm of chromosome 5 (del(5q)) is a frequent clonal chromosomal abnormality in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), 1 and is thought to contribute to the pathogenesis of these diseases by deleting one or more tumor-suppressor genes. 2 MDS with del(5q) is a heterogeneous disease, 3, 4 apart from 5q-syndrome, 5, 6 and often accompanies additional cytogenetic abnormalities leading to the poor-risk karyotypes, or an increase of bone marrow and/or peripheral blasts irrespective of chromosomal complexity. These distinct disease subgroups have dramatically different prognostic features. 3, 5, 7, 8 The international prognostic scoring system (IPSS), defined by bone marrow blast percentage, number of peripheral cytopenias and cytogenetic pattern, has become a benchmark for clinical decision making. 9 Recently, on the other hand, the World Health Organization (WHO) classification-based prognostic scoring system (WPSS) has been proposed based on WHO classification, 10 cytogenetic pattern and transfusion dependency as independent indicators of disease severity. 11 To elucidate the prognostic features of Japanese del(5q) MDS patients, we adapted IPSS, WHO criteria and WPSS to 131 MDS patients with del(5q), 52 patients with monosomy 5 (À5) and 375 MDS patients who did not carry chromosome 5 abnormality, to estimate the mortality rates and life expectancy of these groups as the base for adapting treatments.
Materials and methods

Patient data
A total of 50 MDS patients with chromosome 5 abnormalities were collected in the first series of the survey within 425 MDS patients recorded by the Japanese Cooperative Study Group for Intractable Bone Marrow Diseases. Of 375 patients who did not carry chromosome 5 abnormality in this series were used as controls. In addition to these 50 patients, we conducted a retrospective survey on MDS patients with chromosome 5 abnormalities across 285 hospitals in Japan. A total of 133 cases were newly collected.
A total of 558 MDS patients were collected and 183 patients with chromosome 5 abnormalities and 375 patients with a morphologically normal chromosome 5 were analyzed for (1) additional chromosomal abnormalities, (2) French American and British (FAB) and WHO criteria, (3) IPSS and WPSS, [9] [10] [11] [12] (4) clinical outcome and (5) degree of cytopenia. MDS patients with chromosome 5 abnormalities were classified according to FAB and WHO criteria in Table 1 .
Categorization of del(5q) MDS by additional chromosomal abnormalities
Fifty-two patients with À5 were initially separated, and then del(5q) patients were assigned to one of four cytogenetic categories according to their karyotypes: del(5q) alone as 5q-that included 5q-syndrome, del(5q) with additional chromosome 7 abnormality as (7 þ ), del(5q) with more than three abnormalities as 'complex' and del(5q) patients with cytogenetic aberrations other than 7 þ and complex defined as 'other'. Of 131 del(5q) patients, 35 patients were categorized as 5q-, 47 were 7 þ , 35 were complex and 14 were other.
Statistical analysis
First, statistical test of homogeneity between the two patient data collections was carried out. Actuarial probability of overall survival (OS) and leukemia-free survival (LFS) were estimated using the Kaplan-Meier product limit method. OS was defined as the time between diagnosis and death of any cause or end of follow-up. LFS was calculated from diagnosis to leukemic progression or end of follow-up. Patients who died before leukemic progression were considered as censored at the time of death and those who received stem cell transplantation were censored at the time of transplantation. Comparisons between Kaplan-Meier curves were carried out by Gehan's Wilcoxon's test. To assess the relation of cytogenetic abnormalities with hematological values, Mann-Whitney's U-test was carried out using the hemoglobin concentration, neutrophil and platelet count.
Univariate analyses were performed by w 2 -test and multivariate analyses were performed by Cox proportional hazard regression model. The data were considered statistically significant if P-values were less than 0.05. These analyses were carried out using SPSS for Windows version14.0. The whole study was in accordance with the modified Declaration of Helsinki.
Results
Patient characteristics
As the data of patients with chromosome 5 abnormalities were collected in two cohorts, we performed the statistical test of homogeneity between the two data collections on such factors as patient ages, gender, WHO classification, hemoglobin concentration, neutrophil and platelet counts, degree of red cell transfusion dependency and confirmed that the two groups were not statistically different each other.
Total patient characteristics are listed in Table 1 . The median age of patients with chromosome 5 abnormalities was 69 years and the male-to-female ratio was 113/70, the median age of patients with del(5q) was 69 years and the male/female ratio was 80/51, consistent with the well-known male predominance of MDS. Of the 183 patients, 131 (71.5%) were del(5q) patients with or without other chromosomal abnormalities, 21 (11%) were 5q-syndrome and 52 (28.4%) were À5. Here we defined the cases with macrocytic red cells, isolated del(5q), bone marrow blasts less than 5% as 5q-syndrome. Two refractory cytopenia with multilineage dysplasia (RCMD) cases with isolated del(5q) were excluded because of microcytic anemia without iron deficiency or detection of t(5;17) by further analysis.
Of 425 Japanese MDS patients recorded in the Japanese Cooperative Study Group for Intractable Bone Marrow Diseases, 50 (11.8%) had chromosome 5 abnormalities; therefore, the estimated rate of del(5q) patients and 5q-syndrome among MDS patients was 8.4 and 1.3%, respectively. The incidence of 5q-syndrome proved to be quite rare in Japan.
Impact of chromosome 5 abnormalities on cytopenia
As compared with MDS patients who did not have chromosome 5 abnormality, patients with chromosome 5 abnormalities had significantly severe anemia, whereas no significant difference in the degree of anemia was observed between patients with del(5q) without 5q-syndrome, À5 and 5q-syndrome ( Figure 1a and inset table of Figure 1c ). Except for 5q-syndrome patients, neutropenia was significantly severe in patients with chromosome 5 abnormalities (Figure 1b and inset table of Figure 1c ). Significant thrombocytopenia was observed in À5 patients as compared with del(5q) patients and patients without chromosome 5 abnormality (Figure 1c and inset table) . As expected, the platelet count of 5q-syndrome patients remained within the normal range, which was significantly higher than that of del(5q) excluding 5q-syndrome.
Impact of chromosome 5 abnormalities on survival
Although the median OS of MDS patients without chromosome 5 abnormality was 2358 days, that of patients with chromosome 5 abnormalities was 454 days and significantly short (Figure 2a ). To analyze more precisely, patients with chromosome 5 abnormalities were divided into 5q-syndrome, del(5q) excluding 5q-syndrome and (À5) patients. In total, 52 patients were classified as À5, 110 patients were classified as del(5q) excluding 5q-syndrome and 21 were categorized as 5q-syndrome. The median OS of 5q-syndrome was over 6000 days but that of del(5q) excluding 5q-syndrome and À5 was 501 days and 210 days, respectively. 
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It is noteworthy that none of the 5q-syndrome patients died of leukemic progression. The median LFS of patients without chromosome 5 abnormality was over 6000 days but that of patients with del(5q) excluding 5q-syndrome was 4176 days and significantly short (Figure 2b ). The median LFS of À5 was 2199 days.
Of 52 patients with À5, 37 carried monosomy 7 together, whereas 47 of 131 del(5q) patients did, which indicated that MDS patients with À5 carry monosomy 7 together in a significantly higher incidence than del(5q) patients (w 2 -test, Po0.001). Figure 3a shows that the median OS of 5q-and other was both over 6000 days with no significant difference between the two groups (P ¼ 0.329). The median OS of 7 þ and complex was 240 and 458 days, respectively, and there were significant differences between 5q-and 7 þ (Po0.001), between 5q-and complex (Po0.001). 7 þ patients had a significant shorter OS than complex (P ¼ 0.018).
The median LFS of 5q-and other was over 6000 days and 4176 days, respectively, without significant difference (P ¼ 0.699). The median LFS of 7 þ and complex was 770 days and 5247 days, respectively. 5q-group showed significantly longer LFS than 7 þ (P ¼ 0.006). No significant difference was observed between 5q-and complex (P ¼ 0.069), between 5q-and other (P ¼ 0.699) and between 7 þ and complex (P ¼ 0.236), respectively.
Survival analysis according to IPSS
According to IPSS, of 131 del(5q) patients, 11 were categorized as low-risk and their median OS was over 1800 days, 37 patients were as Intermediate (Int)-1 risk with a median OS of 2863 days, 50 patients as Int-2 risk with a median OS of 501 days and 33 as high risk with a median OS of 248 days (Figure 3b ). Significant shorter OS was observed in high-risk than in low-risk group, Int-1 and Int-2. Int-1 group showed a significantly longer OS than Int-2. No significant difference in OS was observed between low and Int-1 (P ¼ 0.423), and low and Int-2 (P ¼ 0.058), respectively ( Figure 3b) .
Next, as shown in Figure 3c , the median LFS of low-risk group, Int-1, Int-2 and high risk was over 1800 days, over 6000 days, 1682 days and 770 days, respectively. Significant difference in LFS was observed between low-risk and Int-2, between low risk and high risk, between Int-1 and Int-2 and between Int-1 and high risk.
Impact of WHO classification-based prognosis scoring system on survival of MDS patients with del(5q)
Of 131 del(5q) patients, 106 had information concerning transfusion dependency. We categorized these patients according to the WPSS. Of these 6 patients were categorized as very Nationwide survey of MDS with chromosome 5 abnormality T Tasaka et al low risk, 13 as low risk, 16 as Int, 29 as high and 42 as very high. As for patients categorized by WPSS, the patterns of LFS were divided into two groups such as very low/low/Int and high/very high Figure 3d ). Although the duration of observation was short, none of the very low-risk group and only one case of the lowrisk group progressed to leukemia. Hence, we divided IPSS and WPSS classifications into lowerrisk and higher-risk groups; that is, low/Int-1 and Int-2/high in IPSS and very low/low/Int and high/very high in WPSS described above, respectively. We then applied our patient data to each scoring system and calculated the statistic sensitivity to divide the outcome of each patient into: (1) 'alive or dead' and (2) 'leukemia-free or leukemic transformation'. The sensitivity for dividing the events 'alive or dead' was 75.6% in IPSS and 85.4% in WPSS. Likewise, the sensitivity to divide into 'leukemia-free or leukemic transformation' was 78.3% in IPSS and 95.7% in WPSS. These data demonstrated that WPSS was able to predict the outcome of MDS patients with del(5q) more clearly than IPSS.
Determination of prognostic factors in MDS patients with del(5q)
As the univariate analysis, age, gender, hemoglobin concentration, platelet count, neutrophil count, percentage of bone marrow blasts, cytogenetic pattern, red cell transfusion dependency and platelet transfusion dependency were examined. Table 2 indicates the relevant factors for death and leukemic progression rates in the del(5q) patients. This analysis showed Shows statistically significant differences.
Nationwide survey of MDS with chromosome 5 abnormality T Tasaka et al that the major risk factors for death rate were the percentage of bone marrow blasts, cytogenetic pattern and platelet transfusion dependency. It was not significant whether the degree of anemia influences the outcome. The only major factor for leukemic progression was neutrophil count. We further investigated the prognostic factors by multivariate analyses using Cox proportional hazard regression model with fixed covariates and found that the most significant independent risk factors for determining outcome were the percentage of bone marrow blasts, cytogenetic pattern and platelet transfusion dependency ( Table 3 ). The major factors predictive of leukemia progression were the cytogenetic pattern, the presence of neutropenia and thrombocytopenia. Multivariate analyses excluding the influence of red cell and platelet transfusion dependency revealed that the risk factors for OS were bone marrow blasts (P ¼ 0.044) and cytogenetic pattern (Po0.001), and the risk factors for LFS were neutrophil count (P ¼ 0.026), platelet count (P ¼ 0.023) and cytogenetic pattern (P ¼ 0.008). In contrast, Multivariate analyses excluding the influence of hemoglobin concentration and platelet count revealed that cytogenetic pattern was a risk factors for OS (P ¼ 0.003) but neither red cell nor platelet transfusion dependency was a statistically significant risk factor for OS.
Discussion
The biological and clinical significances of À5 and deletion of the long arm of chromosome 5 (del(5q)) are accepted as equivalent, or at least quite similar, in patients with AML and Shows statistically significant differences.
Nationwide survey of MDS with chromosome 5 abnormality T Tasaka et al MDS. [13] [14] [15] In fact, the prognostic value of these two chromosome aberration groups was not significantly different among AML patients, 15 but sufficient data for MDS were lacking. The present study demonstrates that the prognosis of patients who carry À5 and del(5q) are significantly different, as OS and LFS of À5 group were shorter than del(5q) patients even if 5q-syndrome patients were excluded from del(5q) patients (Figure 2 and data not shown). AML patients with monosomy 7 rather than with deleted 7q chromosome were reported to lead to poor prognosis. 16 Significantly poor prognosis of À5 group in our series might be explained by the observation that À5 was significantly correlated with presence of monosomy 7 as compared to del(5q) group (Po0.001). The co-presence of chromosomes 5 and 7 abnormalities has been associated with poor outcomes in MDS and AML. [17] [18] [19] [20] [21] [22] Although the cause of leukemic progression is unknown, susceptibility to leukemia clearly leads to higher mortality of À5 patients compared to del(5q) patients (Figure 2b) . The À5 group also had significantly more severe neutropenia and thrombocytopenia and might exacerbate the survival of this group (Figures  1b and c) . Neutropenia and thrombocytopenia, but not severe anemia, are reported to be common findings of patients with monosomy 7.
23 Taken together, laboratory findings shown in À5 group and high incidence of the co-presence of À5 and monosomy 7 might result in poor prognosis of the corresponding patients.
In this survey, the incidence of 5q-syndrome was quite rare in Japan. Recent studies suggest different genetic or environmental backgrounds between Asian and Western MDS populations. 24, 25 According to the recent report by Haase et al., 28 isolated del(5q) was seen in 14%, del(5q) with one additional abnormality in 5%, and complex abnormalities including del(5q) were seen in 11% of patients with clonal abnormalities. In the Korean study, isolated del(5q) was seen in 1.7% of the patients. 24 The incidence of del(5q), isolated del(5q) and 5q-syndrome patients was 8.4, 2.2 and 1.3%, respectively, in Japanese MDS study. These data are lower than those of Western patients but more similar to those of Asian patients. [24] [25] [26] In the present study, we paid particular attention to MDS patients with del(5q) and classified them into four groups according to the cytogenetic complexity: 5q-, 7 þ , complex and other. 5q-patients have previously been well defined as having relatively good prognosis, whereas poor prognosis was indicated when it was combined with other anomalies. 19, 20, 26, 27 OS and LFS of 7 þ group were significantly shorter than 5q-group and OS of complex was significantly shorter than 5q- (Figure 3a and data not shown). It is suggested that the clinical outcome of MDS patients with del(5q) depends on the prognostic value of combined chromosomal abnormalities.
The most significant independent prognostic variables in MDS are the percentage of bone marrow blasts, the number of cytopenias and cytogenetic pattern. By weighting these variables according to their statistic power, IPSS separates MDS patients into four distinct risk groups regarding survival and the potential for leukemic progression: low risk, Int-1, Int-2 and high risk. 10 Even in the del(5q) patient group, which is considered to have a better prognosis, univariate analysis and multivariate analysis of del(5q) patients in our series showed that the cytogenetic pattern, percentage of bone marrow blasts and platelet transfusion dependency were the most relevant risk factors (Tables 2 and 3) . Figures 3b and c show that IPSS critically determines OS and LFS of del(5q) patients. All 21 patients classified as 5q-syndrome were low risk of IPSS, and the patients classified as high risk were AML and refractory anemia with excess blasts (RAEB)-2 cases with adverse chromosomal abnormalities.
As for the del(5q) patients who are far from the risk of leukemic progression, red cell transfusion dependency often has an adverse impact on survival. 28 Although red cell transfusion dependency was not a significant prognostic factor by the present analyses, the degree of anemia had a tendency to affect survival of these patients from the result of univariate analysis (P ¼ 0.059, Table 2 ).
Although IPSS is based on FAB classification and does not take into account other prognostic factors such as dysplasia and transfusion requirement, WPSS has a relevant prognostic value. 29 Therefore, we applied WPSS to our patient data ( Figure 3d ) and confirmed that WPSS can predict the prognosis of del(5q) MDS patients more clearly than IPSS.
Our study demonstrated that À5 and del(5q) belong to different clinical entities and their biological behaviors are different from each other, and that del(5q) patients can be stratified according to their additional chromosomal abnormalities and IPSS or WPSS status. Severe anemia requires frequent transfusions, reduces quality of life and becomes often the major clinical problem for MDS patients with del(5q). The prognosis of del(5q) patients is related to their status of chromosomal abnormalities and transfusion dependency, but new agents such as lenalidomide improve the disorder and might provide new insights into more precise understanding of the disease. 30 
